Literature DB >> 24234585

Clinical and research applications of simultaneous positron emission tomography and MRI.

F Fraioli1, S Punwani.   

Abstract

Evaluation of the molecular processes responsible for disease pathogenesis and progression represents the new frontier of clinical radiology. Multimodality imaging lies at the cutting edge, combining the power of MRI for tissue characterization, microstructural appraisal and functional assessment together with new positron emission tomography (PET) tracers designed to target specific metabolic processes. The recent commercial availability of an integrated clinical whole-body PET-MRI provides a hybrid platform for exploring and exploiting the synergies of multimodal imaging. First experiences on the clinical and research application of hybrid PET-MRI are emerging. This article reviews the rapidly evolving field and speculates on the potential future direction.

Mesh：

Year:  2013        PMID： 24234585      PMCID： PMC3898970          DOI： 10.1259/bjr.20130464

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


  106 in total

1.  Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI.

Authors:  Ali Afshar-Oromieh; Frederik L Giesel; Heinz G Linhart; Uwe Haberkorn; Sabine Haufe; Stephanie E Combs; Dino Podlesek; Michael Eisenhut; Clemens Kratochwil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-05       Impact factor: 9.236

2.  Substructural hippocampal glucose metabolism observed on PET/MRI.

Authors:  Zang-Hee Cho; Young-Don Son; Hang-Keun Kim; Sung-Tae Kim; Sang-Yoon Lee; Je-Geun Chi; Chan-Woong Park; Young-Bo Kim
Journal:  J Nucl Med       Date:  2010-09-16       Impact factor: 10.057

Review 3.  Imaging of NETs with PET radiopharmaceuticals.

Authors:  V Ambrosini; P Tomassetti; R Franchi; S Fanti
Journal:  Q J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 2.346

Review 4.  Clinical magnetic resonance imaging of brain tumors at ultrahigh field: a state-of-the-art review.

Authors:  William T C Yuh; Greg A Christoforidis; Regina Maria Koch; Steffen Sammet; Petra Schmalbrock; Ming Yang; Michael V Knopp
Journal:  Top Magn Reson Imaging       Date:  2006-04

5.  Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging.

Authors:  Markus Uhl; Ulrich Saueressig; Miriam van Buiren; Udo Kontny; Charlotte Niemeyer; Gabriele Köhler; Kamil Ilyasov; Mathias Langer
Journal:  Invest Radiol       Date:  2006-08       Impact factor: 6.016

Review 6.  New PET radiopharmaceuticals beyond FDG for brain tumor imaging.

Authors:  B Gulyás; C Halldin
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-04       Impact factor: 2.346

7.  Synthesis of 18F-labelled 2-(4'-fluorophenyl)-1,3-benzothiazole and evaluation as amyloid imaging agent in comparison with [11C]PIB.

Authors:  K Serdons; T Verduyckt; D Vanderghinste; J Cleynhens; P Borghgraef; P Vermaelen; C Terwinghe; F Van Leuven; K Van Laere; H Kung; G Bormans; A Verbruggen
Journal:  Bioorg Med Chem Lett       Date:  2008-12-24       Impact factor: 2.823

Review 8.  Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer.

Authors:  John V Hegde; Robert V Mulkern; Lawrence P Panych; Fiona M Fennessy; Andriy Fedorov; Stephan E Maier; Clare M C Tempany
Journal:  J Magn Reson Imaging       Date:  2013-05       Impact factor: 4.813

Review 9.  Functional and molecular imaging of localized and recurrent prostate cancer.

Authors:  Kinzya Grant; Maria L Lindenberg; Haytham Shebel; Yuxi Pang; Harsh K Agarwal; Marcelino Bernardo; Karen A Kurdziel; Baris Turkbey; Peter L Choyke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-07       Impact factor: 9.236

10.  Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study.

Authors:  Andrew S Flett; Daniel M Sado; Giovanni Quarta; Mariana Mirabel; Denis Pellerin; Anna S Herrey; Derek J Hausenloy; Cono Ariti; John Yap; Shyam Kolvekar; Andrew M Taylor; James C Moon
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2012-05-25       Impact factor: 6.875
View more
  4 in total

1.  Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma.

Authors:  Christos Sachpekidis; Jens Hillengass; Hartmut Goldschmidt; Jennifer Mosebach; Leyun Pan; Heinz-Peter Schlemmer; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

Review 2.  The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis.

Authors:  R Chowdhury; B Ganeshan; S Irshad; K Lawler; M Eisenblätter; H Milewicz; M Rodriguez-Justo; K Miles; P Ellis; A Groves; S Punwani; T Ng
Journal:  Br J Radiol       Date:  2014-03-06       Impact factor: 3.039

3.  Cerebral metabolism and perfusion in MR-negative individuals with refractory focal epilepsy assessed by simultaneous acquisition of (18)F-FDG PET and arterial spin labeling.

Authors:  Ilaria Boscolo Galazzo; Maria Vittoria Mattoli; Francesca Benedetta Pizzini; Enrico De Vita; Anna Barnes; John S Duncan; Hans Rolf Jäger; Xavier Golay; Jamshed B Bomanji; Matthias Koepp; Ashley M Groves; Francesco Fraioli
Journal:  Neuroimage Clin       Date:  2016-04-12       Impact factor: 4.881

4.  Comparison between simultaneously acquired arterial spin labeling and 18F-FDG PET in mesial temporal lobe epilepsy assisted by a PET/MR system and SEEG.

Authors:  Yi-He Wang; Yang An; Xiao-Tong Fan; Jie Lu; Lian-Kun Ren; Peng-Hu Wei; Bi-Xiao Cui; Jia-Lin Du; Chao Lu; Di Wang; Hua-Qiang Zhang; Yong-Zhi Shan; Guo-Guang Zhao
Journal:  Neuroimage Clin       Date:  2018-06-07       Impact factor: 4.881
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.